Strontium ranelate: An effective solution for diverse fracture risks

Osteoporosis International

Volumn 21, Issue SUPPL. 2, 2010, Pages 431-436

  Ringe, J D ^a  

^a KLINIKUM LEVERKUSEN   (Germany)

Author keywords

Body mass index; Gender; Glucocorticoids; Heredity; Osteoporosis; Smoking; Strontium ranelate

Indexed keywords

ALENDRONIC ACID; CALCIUM; ESTRADIOL; GLUCOCORTICOID; HYDROXYAPATITE; PLACEBO; RISEDRONIC ACID; STRONTIUM RANELATE; TESTOSTERONE; VITAMIN D; BONE DENSITY CONSERVATION AGENT; ORGANOMETALLIC COMPOUND; THIOPHENE DERIVATIVE;

ANDROGEN DEFICIENCY; BACKACHE; BONE DENSITY; BONE DEVELOPMENT; BONE MASS; BONE METABOLISM; BONE STRENGTH; BONE TURNOVER; CALCIUM ABSORPTION; CHRONIC ARTHRITIS; CLINICAL TRIAL (TOPIC); COLLAGEN METABOLISM; CORTICAL BONE; CORTICOSTEROID INDUCED OSTEOPOROSIS; DECISION MAKING; DISEASE ASSOCIATION; ESTRADIOL BLOOD LEVEL; FRACTURE; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MORTALITY; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN INTAKE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY OSTEOPOROSIS; SEX DIFFERENCE; SMOKING; SPINE FRACTURE; TESTOSTERONE BLOOD LEVEL; VERTEBRA FRACTURE; WRIST FRACTURE; X RAY ABSORPTION SPECTROSCOPY; BODY MASS; FEMALE; GENETIC PREDISPOSITION; MALE;

BODY MASS INDEX; BONE DENSITY CONSERVATION AGENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GLUCOCORTICOIDS; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; RISK FACTORS; SMOKING; THIOPHENES;

EID: 78149472198     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1241-2     Document Type: Review

References (40)

1. Meunier PJ, Roux C, Seeman E et al (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
2. Reginster JY, Seeman E, De Vernejoul MC et al (2005) Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90:2816-2822
3. Ringe JD (2000) Osteoporosis in men. In: Hosking D, Ringe J (eds) Treatment of metabolic bone disease. Management strategy and drug therapy. Martin Dunitz, London
4. Gennari L, Bilezikian JP (2007) Osteoporosis in men. Endocrinol Metab Clin N Am 36:399-419
5. National Osteoporosis Foundation (NOF) (2005) America's bone health: the state of osteoporosis and low bone mass. National Osteoporosis Foundation, Washington
6. EPOS Group (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716-724
7. Sambrook P, Cooper C (2006) Osteoporosis. Lancet 367:2010-2018
8. Szulc P, Delmas PD (2001) Biochemical markers of bone turnover in men. Calcif Tissue Int 89:229-334
9. Fink HA, Ewing SK, Ensrud KB (2006). Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 13908-3915
10. Ebeling PR (2008) Osteoporosis in men. N Engl J Med 358:1474-1482
11. Riggs KS, BL AEJ (2006) Effects of sex and age on bone microstructure at the ultradistal radius: a population-based noninvasive in vivo assessment. J Bone Miner Res 21:124-131
12. Jones G, Nguyen TV, Sambrook PN, Kelly PJ, Bisman JA (1994) Progressive femoral neck bone loss in the elderly: longitudinal findings from the Dubbo Osteoporosis Epidemiology Study. Br Med J 309:691-695
13. Nieves JW, Formica C, Ruffing J, Zion M, Garrett P, Lindsay R, Cosman F (2005) Males have larger skeletal size and bone mass than females, despite comparable body size. J Bone Miner Res 20:529-535
14. Szulc P, Delmas PD (2007) Bone loss in elderly men: increased endosteal bone loss and stable periosteal apposition: the prospective MINOS study. Osteoporos Int 18:495-503
15. Hannan MT, Tucker KL, Dawson-Hughes B, Cupples LA, Felson DT, Kiel DP (2000) Effect of dietary protein on bone loss in elderly men and women: the Framingham Osteoporosis Study. J Bone Miner Res 15:2504-2512
16. Ringe JD (2010) Osteoporosis in men. Medicographia 32:71-78
17. Bonnelye E, Chabadel A, Saltel F, Jurdic P (2008) Dual effect of strontium ranelate: stimulation of osteoblast differentiation and inhibition of osteoclast formation and resorption in vitro. Bone 42:129-138
18. Ringe JD, Dorst A, Faber H, Farahmand P (2008) Treatment of osteoporosis in men with strontium ranelate: results of a prospective controlled trial in 152 patients. Osteoporos Int 19 (Suppl):S13
19. Ringe JD, Dorst A, Farahmand P (2009) Treatment of glucocorticoid-induced osteoporosis with strontium ranelate: a 2-year observational, controlled study versus risedronate. Osteoporos Int 20(Suppl1):S72
20. Bruyère O, Delferriere D, Roux C (2008) Effects of strontium ranelate on spinal osteoarthritis progression. Ann Rheum Dis 67:335-339
21. Ringe JD, Dorst A, Farahmand P. The efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Drug Res Accept Pub
22. Ringe JD, Fahramand P (2007) Advances in the management of corticoid-induced osteoporosis with bisphosphonates. Clin Rheumatol 26:474-478
23. Canalis E, Mazzioti G, Guistina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 10:1319-1328
24. van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993-1000
25. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, Dalsky GP, Marcus R (2007) Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 357:2028-2039
26. Compston J, Reid DM, Boisdron J et al (2009) Recommendations for registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos Int 20:497-498
27. Torgerson DJ, Campbell MK, Thomas RE et al (1996) Prediction of perimenopausal fractures by bone mineral density and other risk factors. J Bone Miner Res 11:293-297
28. Kanis JA, Burliet N, Cooper C et al (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
29. Ferrari S, Ringe JD (2010) Pathophysiology of postmenopausal osteoporosis. In: Rizzoli R (ed) Atlas of postmenopausal osteoporosis, 3rd edn. Current Medicine Group, London
30. Soroko S, Barrett-Connor E, Edelstein S, Kritz-Silverstein D (1994) Family history of osteoporosis and bone mineral density at the axial skeleton: the Rancho Bernardo Study. J Bone Miner Res 9:761-769
31. Ralston SH (2002) Genetic control of susceptibility to osteoporosis. J Clin Endocrinol Metab 87:2460-2466
32. Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawicki A, Tulassay Z et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536-542
33. Forsen L, Bjorndal A, Bjartveit K et al (1994) Interaction between current smoking, leanness, and physical inactivity in the prediction of hip fracture. J Bone Miner Res 9:1671-1678
34. Law MR, Hackshaw AK (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 315:841-846
35. Cornuz J, Feskanich D, Willett W, Colditz G (1999) Smoking, smoking cessation, and risk of hip fracture in women. Am J Med 106:311-314
36. Hassager C, Christiansen C (1993) Influence of soft tissue body composition on bone mass and metabolism. Bone 10:415-419
37. Edelstein SL, Barett-Connor E (1993) Relation between body size and bone mineral density in elderly men and women. Am J Epidemiol 138:160-169
38. Omland LM, Tell GS, Ofjord S, Skag A (2000) Risk factors for low bone mineral density among a large group of Norwegian women with fractures. Eur J Epidemiol 16:223-229
39. Ravn P, Cizza G, Bjarnason NH, Thompson D, Daley M, Wasnich RD et al (1999) Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmeno-pausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res 14:1622-1627
40. Ringe JD, Doherty JG. Absolute risk reduction in osteoporosis: assessing treatment efficacy by number needed to treat. Rheumatol Int doi:10-1007/500296- 009-1311-y